Literature DB >> 22959988

Effect of the vaccination scheme on PregSure® BVD induced alloreactivity and the incidence of Bovine Neonatal Pancytopenia.

Rahel Kasonta1, Carola Sauter-Louis, Mark Holsteg, Karin Duchow, Klaus Cussler, Max Bastian.   

Abstract

Bovine Neonatal Pancytopenia (BNP) is a new neonate-maternal incompatibility phenomenon caused by vaccine-induced, maternal alloantibodies. The syndrome affects newborn calves at the approximate age of ten days and is characterized by spontaneous bleeding, severe anemia with an almost complete destruction of the red bone marrow. During the past two years the causal role of bioprocess impurities in PregSure(®)BVD, a strongly adjuvanted, inactivated vaccine against Bovine Virus Diarrhoea (BVD), in the induction of BNP causing alloantibodies has clearly been established. Despite intensive research efforts that have elucidated the basic principles of the BNP immunopathology still a number of questions remain open. In the current manuscript we address the puzzling observation that BNP incidences vary widely between different regions: as an example we compare the BNP incidences in the German Federal States of Bavaria and Lower Saxony. In Bavaria the BNP-incidence reaches 100 cases per 100,000 doses PregSure(®)BVD, while in Lower Saxony the incidence is as low as 6 cases per 100,000 doses. In Bavaria the vaccine has always been used according to the instructions for use. By contrast, in Lower Saxony BVD-immunization was performed according to a two-step vaccination protocol including a first immunization with an inactivated BVD-vaccine followed by booster immunizations with a live-attenuated BVD-vaccine. As a consequence, those cattle that received PregSure(®)BVD received in general more than two doses in Bavaria, while in Lower Saxony cows received at maximum one dose. By experimental immunization we can show that the two-step regimen including PregSure(®)BVD as a priming vaccine results in significantly lower alloantibody titers as compared to repetitive immunizations with the inactivated vaccine. The lower alloantibody titer after two-step vaccination explains the lower BNP-incidence in Lower Saxony and - generally speaking - indicates that variations in the vaccination regimen have a great influence on the induction of adverse reactions through bioprocess impurities.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22959988     DOI: 10.1016/j.vaccine.2012.08.069

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  A novel RNAseq-assisted method for MHC class I genotyping in a non-model species applied to a lethal vaccination-induced alloimmune disease.

Authors:  Wiebke Demasius; Rosemarie Weikard; Frieder Hadlich; Johannes Buitkamp; Christa Kühn
Journal:  BMC Genomics       Date:  2016-05-17       Impact factor: 3.969

2.  Calf-level factors associated with bovine neonatal pancytopenia--a multi-country case-control study.

Authors:  Bryony A Jones; Carola Sauter-Louis; Joerg Henning; Alexander Stoll; Mirjam Nielen; Gerdien Van Schaik; Anja Smolenaars; Matthijs Schouten; Ingrid den Uijl; Christine Fourichon; Raphael Guatteo; Aurélien Madouasse; Simon Nusinovici; Piet Deprez; Sarne De Vliegher; Jozef Laureyns; Richard Booth; Jackie M Cardwell; Dirk U Pfeiffer
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

3.  Bovine Neonatal Pancytopenia is a heritable trait of the dam rather than the calf and correlates with the magnitude of vaccine induced maternal alloantibodies not the MHC haplotype.

Authors:  Lindert Benedictus; Henny G Otten; Gerdien van Schaik; Walter G J van Ginkel; Henri C M Heuven; Mirjam Nielen; Victor P M G Rutten; Ad P Koets
Journal:  Vet Res       Date:  2014-12-17       Impact factor: 3.683

4.  Colostrum from cows immunized with a vaccine associated with bovine neonatal pancytopenia contains allo-antibodies that cross-react with human MHC-I molecules.

Authors:  Rahel Kasonta; Mark Holsteg; Karin Duchow; James W Dekker; Klaus Cussler; Justin G Bendall; Max Bastian
Journal:  PLoS One       Date:  2014-10-09       Impact factor: 3.240

5.  Evidence of a high incidence of subclinically affected calves in a herd of cattle with fatal cases of Bovine Neonatal Pancytopenia (BNP).

Authors:  Charlotte R Bell; Morag G Kerr; Philip R Scott; W Ivan Morrison; Helen Brown
Journal:  BMC Vet Res       Date:  2014-10-08       Impact factor: 2.741

Review 6.  Control of Bovine Viral Diarrhea.

Authors:  Volker Moennig; Paul Becher
Journal:  Pathogens       Date:  2018-03-08

7.  Spatial distribution and incidence of bovine neonatal pancytopenia in Bavaria, Germany.

Authors:  Carola M Sauter-Louis; Christoph Staubach; Frederike Reichmann; Alexander Stoll; Günter Rademacher; Klaus Cussler; Max Bastian; Annette Pfitzner-Friedrich
Journal:  BMC Vet Res       Date:  2020-05-24       Impact factor: 2.741

8.  Pathogenicity of Bovine Neonatal Pancytopenia-associated vaccine-induced alloantibodies correlates with Major Histocompatibility Complex class I expression.

Authors:  Lindert Benedictus; Rutger D Luteijn; Henny Otten; Robert Jan Lebbink; Peter J S van Kooten; Emmanuel J H J Wiertz; Victor P M G Rutten; Ad P Koets
Journal:  Sci Rep       Date:  2015-08-03       Impact factor: 4.379

9.  Monitoring the immune response to vaccination with an inactivated vaccine associated to bovine neonatal pancytopenia by deep sequencing transcriptome analysis in cattle.

Authors:  Wiebke Demasius; Rosemarie Weikard; Frieder Hadlich; Kerstin Elisabeth Müller; Christa Kühn
Journal:  Vet Res       Date:  2013-10-07       Impact factor: 3.683

10.  Herd-level animal management factors associated with the occurrence of bovine neonatal pancytopenia in calves in a multi-country study.

Authors:  Carola Sauter-Louis; Bryony A Jones; Jörg Henning; Alexander Stoll; Mirjam Nielen; Gerdien Van Schaik; Anja Smolenaars; Matthijs Schouten; Ingrid den Uijl; Christine Fourichon; Raphael Guatteo; Aurélien Madouasse; Simon Nusinovici; Piet Deprez; Sarne De Vliegher; Jozef Laureyns; Richard Booth; Jacqueline M Cardwell; Dirk U Pfeiffer
Journal:  PLoS One       Date:  2017-07-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.